Telix Pharmaceuticals Ltd
TLX7.800USD
-0.010-0.13%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
0.00Market Cap
--P/E TTM
More Details of Telix Pharmaceuticals Ltd Company
Telix Pharmaceuticals Limited is an Australia-based biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. It is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Its segments include Therapeutics, Precision Medicine and Telix Manufacturing Solutions. Therapeutics segment develops targeted radionuclide therapies for urologic, neurologic, musculoskeletal and hematological cancers. Precision Medicine segment focuses on bringing diagnostic imaging solutions to market. Precision Medicine segment also includes MedTech and International businesses. Telix Manufacturing Solutions segment is its global network of facilities designed to deliver patient doses worldwide. Its pipeline products include TLX591, TLX250, TLX101, TLX66, TLX592, TLX252, TLX400, Illuccix (68Ga-PSMA-11) and TLX007-CDx.
Telix Pharmaceuticals Ltd Info
Ticker SymbolTLX
Company nameTelix Pharmaceuticals Ltd
IPO dateNov 15, 2017
CEOOrtiz (Raphaeel)
Number of employees- -
Security typeDepository Receipt
Fiscal year-end- -
Address55 Flemington Road
CityMELBOURNE
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryAustralia
Postal code3051
Phone61390933855
Websitehttps://telixpharma.com/
Ticker SymbolTLX
IPO dateNov 15, 2017
CEOOrtiz (Raphaeel)
Company Executives of Telix Pharmaceuticals Ltd
Name
Name/Position
Position
Shareholding
Change
Ms. Marie McDonald
Ms. Marie McDonald
Non-Executive Director
Non-Executive Director
--
--
Dr. Paul Schaffer
Dr. Paul Schaffer
Chief Technology Officer
Chief Technology Officer
--
--
Mr. Richard Valeix
Mr. Richard Valeix
Group Chief Commercial Officer
Group Chief Commercial Officer
--
--
Mr. James Stonecypher
Mr. James Stonecypher
Group Chief Development Officer
Group Chief Development Officer
--
--
Dr. Mark Nelson, Ph.D.
Dr. Mark Nelson, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Tiffany P. Olson
Ms. Tiffany P. Olson
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Dr. Christian P. Behrenbruch, J.D., Ph.D.
Dr. Christian P. Behrenbruch, J.D., Ph.D.
Group Chief Executive Officer, Managing Director, Executive Director
Group Chief Executive Officer, Managing Director, Executive Director
--
--
Mr. Darren Smith, CPA
Mr. Darren Smith, CPA
Group Chief Financial Officer
Group Chief Financial Officer
--
--
Ms. Genevieve Ryan
Ms. Genevieve Ryan
Company Secretary
Company Secretary
--
--
Dr. David Cade
Dr. David Cade
Group Chief Medical Officer
Group Chief Medical Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Ms. Marie McDonald
Ms. Marie McDonald
Non-Executive Director
Non-Executive Director
--
--
Dr. Paul Schaffer
Dr. Paul Schaffer
Chief Technology Officer
Chief Technology Officer
--
--
Mr. Richard Valeix
Mr. Richard Valeix
Group Chief Commercial Officer
Group Chief Commercial Officer
--
--
Mr. James Stonecypher
Mr. James Stonecypher
Group Chief Development Officer
Group Chief Development Officer
--
--
Dr. Mark Nelson, Ph.D.
Dr. Mark Nelson, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Tiffany P. Olson
Ms. Tiffany P. Olson
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Thu, Dec 4
Updated: Thu, Dec 4
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Millennium Management LLC
0.06%
Portland Investment Counsel Inc.
0.04%
Fidelity Management & Research Company LLC
0.04%
Lazard Asset Management, L.L.C.
0.03%
Jane Street Capital, L.L.C.
0.02%
Other
99.81%
Shareholders
Shareholders
Proportion
Millennium Management LLC
0.06%
Portland Investment Counsel Inc.
0.04%
Fidelity Management & Research Company LLC
0.04%
Lazard Asset Management, L.L.C.
0.03%
Jane Street Capital, L.L.C.
0.02%
Other
99.81%
Shareholder Types
Shareholders
Proportion
Investment Advisor
0.11%
Hedge Fund
0.06%
Investment Advisor/Hedge Fund
0.05%
Research Firm
0.02%
Other
99.76%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
25
456.14K
0.13%
+379.51K
2025Q2
11
269.45K
0.08%
+265.72K
2025Q1
6
20.71K
0.01%
+16.98K
2024Q4
1
3.73K
0.00%
+3.73K
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Fidelity Management & Research Company LLC
42.09K
0.01%
+42.09K
--
Jun 30, 2025
Jane Street Capital, L.L.C.
35.10K
0.01%
+35.10K
--
Jun 30, 2025
Private Advisor Group LLC
25.17K
0.01%
+15.03K
+148.20%
Jun 30, 2025
IHT Wealth Management, LLC
13.24K
0%
+13.24K
--
Jun 30, 2025
Vanguard Personalized Indexing Management, LLC
18.48K
0.01%
+18.48K
--
Jun 30, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Telix Pharmaceuticals Ltd?
The top five shareholders of Telix Pharmaceuticals Ltd are:
Fidelity Management & Research Company LLC holds 42.09K shares, accounting for 0.01% of the total shares.
Jane Street Capital, L.L.C. holds 35.10K shares, accounting for 0.01% of the total shares.
Private Advisor Group LLC holds 25.17K shares, accounting for 0.01% of the total shares.
IHT Wealth Management, LLC holds 13.24K shares, accounting for 0.00% of the total shares.
Vanguard Personalized Indexing Management, LLC holds 18.48K shares, accounting for 0.01% of the total shares.
Fidelity Management & Research Company LLC holds 42.09K shares, accounting for 0.01% of the total shares.
Jane Street Capital, L.L.C. holds 35.10K shares, accounting for 0.01% of the total shares.
Private Advisor Group LLC holds 25.17K shares, accounting for 0.01% of the total shares.
IHT Wealth Management, LLC holds 13.24K shares, accounting for 0.00% of the total shares.
Vanguard Personalized Indexing Management, LLC holds 18.48K shares, accounting for 0.01% of the total shares.
What are the top three shareholder types of Telix Pharmaceuticals Ltd?
The top three shareholder types of Telix Pharmaceuticals Ltd are:
Millennium Management LLC
Portland Investment Counsel Inc.
Fidelity Management & Research Company LLC
Millennium Management LLC
Portland Investment Counsel Inc.
Fidelity Management & Research Company LLC
How many institutions hold shares of Telix Pharmaceuticals Ltd (TLX)?
As of 2025Q3, 25 institutions hold shares of Telix Pharmaceuticals Ltd, with a combined market value of approximately 456.14K, accounting for 0.13% of the total shares. Compared to 2025Q2, institutional shareholding has increased by 0.06%.
What is the biggest source of revenue for Telix Pharmaceuticals Ltd?
In --, the -- business generated the highest revenue for Telix Pharmaceuticals Ltd, amounting to -- and accounting for --% of total revenue.
